Search

Your search keyword '"Eduardus"' showing total 6 results
Start Over Author "Eduardus" Publication Year Range Last 10 years Journal annals of hematology
6 results on '"Eduardus"'

3. Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia

Author

Avinash G. Dinmohamed, Esther C. van den Broek, Arnon P. Kater, Jeanette K. Doorduijn, Mark-David Levin, Eduardus F. M. Posthuma, Lina van der Straten, Experimental Immunology, Clinical Haematology, CCA - Cancer Treatment and Quality of Life, Hematology, and Public Health

Subjects
Oncology, medicine.medical_specialty, Registry, Chronic lymphocytic leukemia, medicine.medical_treatment, Population, Population-based, 03 medical and health sciences, 0302 clinical medicine, Cancer epidemiology, immune system diseases, Internal medicine, hemic and lymphatic diseases, Epidemiology of cancer, Clinical endpoint, Medicine, Chemotherapy, education, education.field_of_study, Hematology, business.industry, Hazard ratio, General Medicine, medicine.disease, 030220 oncology & carcinogenesis, Rituximab, business, 030215 immunology, medicine.drug
Abstract

Rituximab-containing chemotherapy remains a viable frontline treatment option for patients with chronic lymphocytic leukemia (CLL) in the era of novel agents. However, its effectiveness in the second-line setting—in relation to previous rituximab exposure in first-line—has hardly been evaluated in a population-based setting. Therefore, in this comprehensive, population-based study, we assessed the impact of first-line treatment with rituximab-containing chemotherapy on the effectiveness of second-line treatment with rituximab-containing chemotherapy. We selected all 1735 patients diagnosed with CLL between 2004 and 2010 from the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). The primary endpoint was treatment-free survival (TFS). First- and second-line treatment was instituted in 663 (38%) and 284 (43%) patients, respectively. In first line, the median TFS was 19.7 and 67.1 months for chemotherapy without (n = 445; 67%) and with rituximab (n = 218; 33%), respectively (adjusted hazard ratio [HRadjusted], 0.83; P = 0.031). The median TFS among recipients of second-line chemotherapy without (n = 165; 57%) and with rituximab (n = 121; 42%) was 15.0 and 15.3 months, respectively (HRadjusted, 0.93; P = 0.614). Of the 121 patients who received rituximab-containing chemotherapy in second-line, 89 (74%) and 32 (26%) received first-line chemotherapy without and with rituximab, respectively. Median TFS in these two treatment groups was 18.3 and 12.1 months, respectively (HRadjusted, 1.71; P = 0.060). Collectively, in this population-based study, the effectiveness of first-line treatment with rituximab-containing chemotherapy was less pronounced in second-line treatment. The hampered effectiveness of rituximab-containing chemotherapy in second-line could not be explained by previous rituximab exposure.

Published
2020

4. Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia

Author

Lina, van der Straten, Arnon P, Kater, Jeanette K, Doorduijn, Esther C, van den Broek, Eduardus F M, Posthuma, Avinash G, Dinmohamed, and Mark-David, Levin

Subjects
Adult, Male, Adolescent, Drug Resistance, Neoplasm, Humans, Female, Registries, Middle Aged, Rituximab, Leukemia, Lymphocytic, Chronic, B-Cell, Aged, Follow-Up Studies
Abstract

Rituximab-containing chemotherapy remains a viable frontline treatment option for patients with chronic lymphocytic leukemia (CLL) in the era of novel agents. However, its effectiveness in the second-line setting-in relation to previous rituximab exposure in first-line-has hardly been evaluated in a population-based setting. Therefore, in this comprehensive, population-based study, we assessed the impact of first-line treatment with rituximab-containing chemotherapy on the effectiveness of second-line treatment with rituximab-containing chemotherapy. We selected all 1735 patients diagnosed with CLL between 2004 and 2010 from the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). The primary endpoint was treatment-free survival (TFS). First- and second-line treatment was instituted in 663 (38%) and 284 (43%) patients, respectively. In first line, the median TFS was 19.7 and 67.1 months for chemotherapy without (n = 445; 67%) and with rituximab (n = 218; 33%), respectively (adjusted hazard ratio [HR

Published
2019

6. Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands.

Author

Broek, Esther, Oerlemans, Simone, Nijziel, Marten, Posthuma, Eduardus, Coebergh, Jan, and Poll-Franse, Lonneke

Subjects
CHLORAMBUCIL, QUALITY of life, CHRONIC lymphocytic leukemia treatment, CLINICAL trials, ANXIETY disorders, THERAPEUTICS
Abstract

As survival of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) increases and the number of patients who live long rises, health-related quality of life (HRQoL) becomes a relevant endpoint. Few studies investigated this, mainly as a secondary endpoint in randomized clinical trials where patients with early stage CLL/SLL, and elderly/frail patients were underrepresented. The aim of our study was to assess HRQoL in a population-based setting, including these previously underrepresented patients. Out of 175 patients diagnosed with CLL/SLL between 2004 and 2011, 136 (78 %) returned the HRQoL questionnaire. The outcomes were compared to an age- and sex-matched norm population. Detailed data on stage and treatment were extracted from a population-based hematological registry (PHAROS). Patients ever treated for CLL/SLL reported significantly poorer HRQoL than the norm population ( p < 0.01 with large clinically important differences. Interestingly, no differences were observed between the norm population and patients under active surveillance. In contrast to our hypothesis, patients treated with chlorambucil reported the lowest HRQoL scores. Drastic, long-lasting negative effects of starting treatment on HRQoL cannot be excluded, whereas active surveillance does not seem to provoke worrying, anxiety, or depressive symptoms. Further elaborate research into the impact of starting therapy on HRQoL is needed, especially in patients that are underrepresented in most clinical trials, and thoroughly consider its results during revision of treatment guidelines. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results